Table 1 Baseline and clinical characteristics of the 59 patients who were evaluated to validate the 20-item questionnaire
Mean ± SD | |
|---|---|
Number (male-to-female ratio) | 59 (22:37) |
Age (years) | 66.85 ± 8.25 |
Disease duration (years) | 6.14 ± 4.80 |
Treatment duration (years) | 4.43 ± 4.00 |
The daily dose of levodopa (mg/day) | 540.00 ± 296.21 |
K-MMSE | 26.49 ± 2.85 |
New questionnaire | 23.24 ± 22.29 |
HY stage | 2.42 ± 0.58 |
UPDRS | 45.78 ± 18.49 |
Mentation | 3.26 ± 2.05 |
ADL | 11.88 ± 6.22 |
Motor | 27.91 ± 11.05 |
Complications | 2.73 ± 2.97 |
SEADL | 77.59 ± 15.89 |
BDI | 22.38 ± 11.53 |
PDQL | 115.53 ± 39.93 |
Parkinson’s symptoms | 42.51 ± 14.14 |
Systemic symptoms | 25.27 ± 9.64 |
Social function | 19.21 ± 7.18 |
Emotional function subscore | 28.54 ± 10.80 |
ADQ | 19.21 ± 12.42 |
FSS | 36.20 ± 15.69 |